2011, Number 1
Next >>
Rev Hematol Mex 2011; 12 (1)
Some observations on the lag of stem cell grafting in México
Ruiz-Argüelles GJ, Cazares-Ordoñez Y, Ruiz-Delgado GJ
Language: Spanish
References: 17
Page: 1-4
PDF size: 61.93 Kb.
Text Extraction
No abstract
REFERENCES
Sosa-Sánchez R, Córdova MS, Labardini JR, Chávez-Peón F. Trasplante de médula ósea en anemia aplástica. Reporte del primer caso en México. Rev Invest Clín Méx 1980;32:49-55.
Ruiz-Argüelles GJ. Historia del trasplante de médula ósea en México. Rev Hematol Méx 2004;5:80-85.
Ruiz-Argüelles GJ, Gómez-Almaguer D. Making allogeneic bone marrow transplantation available to patients in developing countries: The Mexican Experience. Open Hematol J 2008;2:30-36.
Ruiz-Argüelles GJ, Ruiz-Argüelles A, Pérez-Romano B, Marín- López A, Larregina-Díez A, Apreza-Molina MG. Filgrastim-mobilized peripheral-blood stem cells can be stored at 4 degrees and used in autografts to rescue high-dose chemotherapy. Am J Hematol 1995;48:100-103.
López-Otero A, Ruiz-Delgado GJ, Ruiz-Argüelles GJ. A simplified method for stem cell autografting in multiple myeloma: A single institution experience. Bone Marrow Transplant 2009; 44:715-719.
Vela-Ojeda J, García-Ruiz-Esparza MA, Padilla-Gonzalez Y, Gomez-Almaguer D, Gutierrez-Aguirre CH, Gomez-Rangel D, Morales-Toquero A, Ruiz-Delgado GJ, Delgado-Lamas JL, Ruiz-Arguelles GJ. Autologous peripheral blood stem cell transplantation in multiple myeloma using oral versus IV melphalan. Ann Hematol 2007;86:277-282.
Ruiz-Arguelles GJ. Whither the bone marrow transplant. Hematology 2010;15:1-3
Limón-Flores JA, Pérez-Lozano Uendy, Solís-Poblano JC, Rodríguez-Castillo P, Zagoya-Martínez P. El programa de trasplante hematopoyético del Hospital de Especialidades del IMSS de Puebla: Experiencia de 15 años. Rev Hematol Méx 2010;11(4):179-184.
Gómez-Almaguer D, Ruiz-Argüelles GJ, Ruiz-Argüelles A, González-Llano O, Cantú OE, Hernández NE. Hematopoietic stem cell allografts using a non-myeloablative conditioning regimen can be safely performed on an outpatient basis. Bone Marrow Transpl 2000; 25:131-133.
Ruiz-Argüelles GJ. Allogeneic stem cell transplantation using non-myeloablative conditioning regimens: Results of the Mexican approach. Int J Hematol 2002;76 (Suppl 1): 376-379.
Ruiz-Argüelles GJ, Gómez-Almaguer D. Breaking dogmata to help patients: Non-myeloablative hematopoietic stem cell transplantation. Expert Opin Biol Ther 2004;4:1693-1699.
Ruiz-Argüelles GJ, Gómez-Almaguer D, Morales-Toquero A, Gutiérrez-Aguirre CH, Vela-Ojeda J, García-Ruiz-Esparza MA, Manzano C, Karduss A, Sumoza A, de-Souza C, Miranda E, Giralt S; Latin American Cooperative OncoHematology Group. The early referral for reduced-intensity stem cell transplantation in patients with Ph1 (+) chronic myelogenous leukemia in chronic phase in the imatinib era: Results of the Latin American Cooperative OncoHematology Group (LACOHG) prospective, multicenter study. Bone Marrow Transplant 2005;36:1043-1047.
Saito AM, Zahrich D, Cutler C, Ho VT, Antin JH, et al. Lower costs associated with hematopoietic cell transplantation using reduced intensity vs high-dose regimens for hematological malignancy. Bone Marrow Transplant 2007;40:209-217.
Diaconescu R, Flowers CR, Storer B, Sorror ML, Maris MB, et al. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood 2004;104:1550-1558.
Cantú OG, Gutiérrez H, Ruiz-Argüelles GJ, López A, Mancías C, Martínez S, González O, Jaime J, Gómez D. Incidence of graft versus host disease (GVHD) in patients with allogeneic peripheral hematopoietic stem cell transplantation after a nonmyeloablative conditioning. Haematologica 2010: 95(s2):653.
Ruiz-Argüelles GJ, Gómez-Almaguer D. El efecto Mateo en la medicina mexicana. Bol Méd Hosp Inf Méx 2003;60:452-453.
Ruiz-Argüelles GJ. Editorial: ¿Malinchismo o dicotomía? Algunas reflexiones. Rev Hematol Méx 2010;11:127-128.